CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases 2020

Biocon  /  News – Posts  /  Press Releases  /  Press Releases 2020

Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr

  • Posted by: BIOCON

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

  • Posted by: BIOCON

Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19

  • Posted by: BIOCON

Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients

  • Posted by: BIOCON

Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets

  • Posted by: BIOCON

Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award

  • Posted by: BIOCON

Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®

  • Posted by: BIOCON

Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients

  • Posted by: BIOCON

Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>